Johns Hopkins University researchers have engineered a general-purpose antibody by installing six specific mutations on the fragment crystallizable region to serve as standardized attachment sites for drug-carrying nanoparticles and diagnostic markers. This development matters to tech professionals because it replaces heterogeneous, unpredictable chemical bonding with a tunable, programmable platform that ensures precise drug-to-antibody ratios and consistent formulation quality. Watch for this modular system to streamline automated bioprocessing workflows and enable more scalable manufacturing of targeted therapeutic conjugates.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
